Phase 3
Recruiting

MK-0616 (oral PCSK9 inhibitor)

Sponsored by Merck
Timeline
Study Dates
Start Date
September 2023
Est. Completion
December 2026
Enrollment Target
3000 participants
Status
Recruiting
Study Design
Primary Endpoint
Percent reduction in LDL-C from baseline at Week 52 vs placebo
⚠ No ClinicalTrials.gov registry ID found for this program. This trial was announced but no registered study has been identified. CelluTarget flags this distinction rather than treating announced and registered trials as equivalent.
Related Treatment
Treatment Being Studied
MK-0616 (oral PCSK9 inhibitor)